Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence

被引:127
作者
Burdy, G
Panis, Y
Alves, A
Nemeth, J
Lavergne-Slove, A
Valleur, P
机构
[1] Hop Lariboisiere, Serv Chirurg Gen & Digest, Dept Gen Surg, F-75475 Paris 10, France
[2] Hop Lariboisiere, Dept Pathol, F-75475 Paris 10, France
关键词
colon cancer; adjuvant chemotherapy; tumor recurrence;
D O I
10.1007/BF02234390
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: Adjuvant chemotherapy is effective for node-positive colon cancer patients. In node-negative patients, it could be justified in high-risk patients. The purpose of this study was to determine clinical and pathological findings associated with tumor recurrence in T3-T4 node-negative colon cancer patients. METHODS: From 1974 to 1993, 108 patients undergoing colectomy for T3-4N0M0 colon cancer, without adjuvant chemotherapy, followed until death or for a minimum of five years, were divided into two groups: patients without recurrence (n = 74) and those dead from colon cancer or alive with recurrence (n = 34). Thirty-three clinical and pathological findings were studied. RESULTS: In univariate analysis, the following were significantly associated with a high risk of tumor recurrence: male patients (P = 0.006), bowel obstruction (P < 0.001), weight loss > 5 Kg (P = 0.03), circumferential tumor (P = 0.02), macroscopic or microscopic pericolic organ invasion (T4 stage; P < 0.001), perineural invasion (P = 0.02), vascular invasion (P = 0.045), poor tumor differentiation (P = 0.005), mesocolic invasion > 1 cm (P = 0.009), less than 14 uninvolved nodes on the specimen (P = 0.03), and visceral peritoneal invasion (T4; P < 0.001). In multivariate analysis. the following were independent prognostic factors of recurrence: male patients (P = 0.005), bowel obstruction (P = 0.002), pericolic organ invasion (i.e., T4 tumor; P = 0.02), and less than 14 uninvolved nodes on a specimen (P = 0.01). On the other hand, preoperative carcinoembryonic antigen serum level, size and tumor location, blood transfusion, and mucin production were not associated with higher risk of tumor recurrence. CONCLUSION: Our study identifies a subgroup of patients with node-negative colon cancer at high risk of recurrence, who could be included in priority trials of adjuvant chemotherapy.
引用
收藏
页码:1682 / 1688
页数:7
相关论文
共 45 条
[1]  
Caplin S, 1998, CANCER, V83, P666, DOI 10.1002/(SICI)1097-0142(19980815)83:4<666::AID-CNCR6>3.0.CO
[2]  
2-I
[3]  
CHAPMAN MAS, 1995, CANCER, V76, P383, DOI 10.1002/1097-0142(19950801)76:3<383::AID-CNCR2820760306>3.0.CO
[4]  
2-F
[5]   A MULTIVARIATE-ANALYSIS OF CLINICAL AND PATHOLOGICAL VARIABLES IN PROGNOSIS AFTER RESECTION OF LARGE BOWEL-CANCER [J].
CHAPUIS, PH ;
DENT, OF ;
FISHER, R ;
NEWLAND, RC ;
PHEILS, MT ;
SMYTH, E ;
COLQUHOUN, K .
BRITISH JOURNAL OF SURGERY, 1985, 72 (09) :698-702
[6]   Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer [J].
Erlichman, C ;
O'Connell, M ;
Kahn, M ;
Marsoni, S ;
Torri, V ;
Tardio, B ;
Zaniboni, A ;
Pancera, G ;
Martignoni, G ;
Labianca, R ;
Barni, A ;
Seitz, JF ;
Milan, C ;
Bedenne, L ;
Giovannini, M ;
Letreut, YP ;
Skillings, J ;
Shepard, L ;
Zee, B ;
Petrioli, R ;
Francini, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1356-1363
[7]   FOLINIC ACID AND 5-FLUOROURACIL AS ADJUVANT CHEMOTHERAPY IN COLON-CANCER [J].
FRANCINI, G ;
PETRIOLI, R ;
LORENZINI, L ;
MANCINI, S ;
ARMENIO, S ;
TANZINI, G ;
MARSILI, S ;
AQUINOA ;
MARZOCCA, G ;
CIVITELLI, S ;
MARIANI, L ;
DESANDO, D ;
BOVENGA, S ;
LORENZI, M .
GASTROENTEROLOGY, 1994, 106 (04) :899-906
[8]   Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer [J].
Ganesh, S ;
Sier, CFM ;
Heerding, MM ;
vanKrieken, JHJM ;
Griffioen, G ;
Welvaart, K ;
vandeVelde, CJH ;
Verheijen, JH ;
Lamers, CBHW ;
Verspaget, HW .
BRITISH JOURNAL OF CANCER, 1997, 75 (12) :1793-1801
[9]  
GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO
[10]  
2-D